Published in Cancer Res on July 02, 2012
Function and cancer genomics of FAT family genes (review). Int J Oncol (2012) 1.34
O-GlcNAcylation regulates EZH2 protein stability and function. Proc Natl Acad Sci U S A (2014) 1.09
Differential regulation of extracellular matrix protein expression in carcinoma-associated fibroblasts by TGF-β1 regulates cancer cell spreading but not adhesion. Oncoscience (2014) 1.02
p63/MT1-MMP axis is required for in situ to invasive transition in basal-like breast cancer. Oncogene (2015) 1.02
Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions. Breast Cancer Res (2014) 0.96
Identification of molecular determinants of primary and metastatic tumour re-initiation in breast cancer. Nat Cell Biol (2015) 0.94
FGFR1 amplification and the progression of non-invasive to invasive breast cancer. Breast Cancer Res (2012) 0.89
The retinoblastoma tumor suppressor pathway modulates the invasiveness of ErbB2-positive breast cancer. Oncogene (2013) 0.86
RNA-Seq of human breast ductal carcinoma in situ models reveals aldehyde dehydrogenase isoform 5A1 as a novel potential target. PLoS One (2012) 0.84
Extensive rewiring of epithelial-stromal co-expression networks in breast cancer. Genome Biol (2015) 0.84
The Role of Sentinel Lymph Node Biopsy and Factors Associated with Invasion in Extensive DCIS of the Breast Treated by Mastectomy: The Cinnamome Prospective Multicenter Study. Ann Surg Oncol (2015) 0.82
Association between ALDH1+/CD133+ stem-like cells and tumor angiogenesis in invasive ductal breast carcinoma. Oncol Lett (2016) 0.82
Wild-Type N-Ras, Overexpressed in Basal-like Breast Cancer, Promotes Tumor Formation by Inducing IL-8 Secretion via JAK2 Activation. Cell Rep (2015) 0.81
FAT4 functions as a tumour suppressor in gastric cancer by modulating Wnt/β-catenin signalling. Br J Cancer (2015) 0.81
Systematic identification and characterization of novel human skin-associated genes encoding membrane and secreted proteins. PLoS One (2013) 0.81
Expression of pre-selected TMEMs with predicted ER localization as potential classifiers of ccRCC tumors. BMC Cancer (2015) 0.81
Understanding the role of the kynurenine pathway in human breast cancer immunobiology. Oncotarget (2016) 0.80
Low spinophilin expression enhances aggressive biological behavior of breast cancer. Oncotarget (2015) 0.78
Murine microenvironment metaprofiles associate with human cancer etiology and intrinsic subtypes. Clin Cancer Res (2013) 0.78
Transcriptomic analysis of stage 1 versus advanced adult granulosa cell tumors. Oncotarget (2016) 0.78
Validation of COL11A1/procollagen 11A1 expression in TGF-β1-activated immortalised human mesenchymal cells and in stromal cells of human colon adenocarcinoma. BMC Cancer (2014) 0.77
Association between FAT1 mutation and overall survival in patients with human papillomavirus-negative head and neck squamous cell carcinoma. Head Neck (2016) 0.77
A highly invasive subpopulation of MDA-MB-231 breast cancer cells shows accelerated growth, differential chemoresistance, features of apocrine tumors and reduced tumorigenicity in vivo. Oncotarget (2016) 0.75
Identification of several hub-genes associated with periodontitis using integrated microarray analysis. Mol Med Rep (2014) 0.75
Myoepithelial Cell Differentiation Markers in Ductal Carcinoma in Situ Progression. Am J Pathol (2015) 0.75
Pathomimetic avatars reveal divergent roles of microenvironment in invasive transition of ductal carcinoma in situ. Breast Cancer Res (2017) 0.75
Distinct luminal-type mammary carcinomas arise from orthotopic Trp53-null mammary transplantation of juvenile versus adult mice. Cancer Res (2014) 0.75
The regulation of tumor suppressor protein, p53, and estrogen receptor (ERα) by resveratrol in breast cancer cells. Genes Cancer (2016) 0.75
TMEM45A, SERPINB5 and p16INK4A transcript levels are predictive for development of high-grade cervical lesions. Am J Cancer Res (2016) 0.75
Knockdown of TMEM45A inhibits the proliferation, migration and invasion of glioma cells. Int J Clin Exp Pathol (2015) 0.75
Tumor angiogenesis. N Engl J Med (2008) 11.30
Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell (2004) 9.41
Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA (2003) 8.07
Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci U S A (2003) 6.35
Ontologizer 2.0--a multifunctional tool for GO term enrichment analysis and data exploration. Bioinformatics (2008) 4.74
Regulation of in situ to invasive breast carcinoma transition. Cancer Cell (2008) 4.46
Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin Cancer Res (2008) 3.83
Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res (2009) 3.52
Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res (2004) 2.67
National Institutes of Health State-of-the-Science Conference statement: Diagnosis and Management of Ductal Carcinoma In Situ September 22-24, 2009. J Natl Cancer Inst (2010) 2.59
Molecular markers in ductal carcinoma in situ of the breast. Mol Cancer Res (2003) 2.55
An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ. Breast Cancer Res (2009) 2.37
Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. Cancer Res (2006) 2.36
Plakins in development and disease. Exp Cell Res (2007) 2.36
A SAGE (serial analysis of gene expression) view of breast tumor progression. Cancer Res (2001) 2.22
Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer (1995) 2.01
Ductal carcinoma in situ: state of the science and roadmap to advance the field. J Clin Oncol (2008) 1.74
Transcriptomic changes in human breast cancer progression as determined by serial analysis of gene expression. Breast Cancer Res (2004) 1.71
erbB-2 overexpression in human mammary epithelial cells confers growth factor independence. Endocrinology (1999) 1.60
Classification of ductal carcinoma in situ by gene expression profiling. Breast Cancer Res (2006) 1.59
Identification of early molecular markers for breast cancer. Mol Cancer (2011) 1.45
Changes in CpG islands promoter methylation patterns during ductal breast carcinoma progression. Cancer Epidemiol Biomarkers Prev (2009) 1.43
Molecular characterisation of the tumour microenvironment in breast cancer. Eur J Cancer (2008) 1.39
Senescent stromal-derived osteopontin promotes preneoplastic cell growth. Cancer Res (2009) 1.38
Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma. Breast Cancer Res (2008) 1.38
Molecular mechanisms guiding embryonic mammary gland development. Cold Spring Harb Perspect Biol (2010) 1.37
Epithelial and stromal cathepsin K and CXCL14 expression in breast tumor progression. Clin Cancer Res (2008) 1.31
Alterations of gene expression in the development of early hyperplastic precursors of breast cancer. Am J Pathol (2007) 1.25
Prognostic significance of cysteine proteinases cathepsins B and L and their endogenous inhibitors stefins A and B in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res (2000) 1.08
BPAG1e maintains keratinocyte polarity through beta4 integrin-mediated modulation of Rac1 and cofilin activities. Mol Biol Cell (2009) 1.08
Identification of homozygous deletions of tumor suppressor gene FAT in oral cancer using CGH-array. Oncogene (2007) 1.07
Early dysregulation of cell adhesion and extracellular matrix pathways in breast cancer progression. Am J Pathol (2009) 1.07
Progression of ductal carcinoma in situ to invasive breast cancer is associated with gene expression programs of EMT and myoepithelia. Breast Cancer Res Treat (2011) 1.00
Columnar cell lesions of the breast. Histopathology (2008) 0.97
The relevance of mouse models to understanding the development and progression of human breast cancer. J Mammary Gland Biol Neoplasia (2008) 0.96
Expression of cysteine peptidase cathepsin L and its inhibitors stefins A and B in relation to tumorigenicity of breast cancer cell lines. Cancer Lett (2002) 0.95
Comparative integromics on FAT1, FAT2, FAT3 and FAT4. Int J Mol Med (2006) 0.94
p63-specific activation of the BPAG-1e promoter. J Invest Dermatol (2005) 0.91
Higher expression levels of 14-3-3sigma in ductal carcinoma in situ of the breast predict poorer outcome. Cancer Biomark (2009) 0.89
Ratio of cathepsin B to stefin A identifies heterogeneity within Gleason histologic scores for human prostate cancer. Prostate (2001) 0.83
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol (2006) 25.12
A common genetic variant is associated with adult and childhood obesity. Science (2006) 14.95
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol (2010) 14.41
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol (2009) 9.39
Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature (2012) 8.03
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med (2007) 8.02
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet (2013) 5.58
Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet (2003) 5.40
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA (2011) 4.63
Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst (2003) 4.45
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med (2010) 4.38
Mastectomy and oophorectomy by menstrual cycle phase in women with operable breast cancer. J Natl Cancer Inst (2002) 4.09
Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep (2013) 3.85
Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin Cancer Res (2008) 3.83
Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol (2005) 3.62
Walking and leisure-time activity and risk of hip fracture in postmenopausal women. JAMA (2002) 3.39
Intraclonal competition limits the fate determination of regulatory T cells in the thymus. Nat Immunol (2009) 3.38
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst (2008) 3.21
Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol (2005) 3.18
Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2009) 3.17
Use of sunscreen, sunburning rates, and tanning bed use among more than 10 000 US children and adolescents. Pediatrics (2002) 3.12
Constitutive activation of smoothened (SMO) in mammary glands of transgenic mice leads to increased proliferation, altered differentiation and ductal dysplasia. Development (2007) 3.07
The future of the TNM staging system in colorectal cancer: time for a debate? Lancet Oncol (2007) 2.94
Teamwork in the operating room: frontline perspectives among hospitals and operating room personnel. Anesthesiology (2006) 2.78
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med (2010) 2.72
Antigen-specific peripheral shaping of the natural regulatory T cell population. J Exp Med (2008) 2.68
Relation between changes in intakes of dietary fiber and grain products and changes in weight and development of obesity among middle-aged women. Am J Clin Nutr (2003) 2.68
EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2. Nature (2013) 2.67
Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F-FRGD2. J Nucl Med (2006) 2.65
The histone demethylases Jhdm1a/1b enhance somatic cell reprogramming in a vitamin-C-dependent manner. Cell Stem Cell (2011) 2.65
Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol (2004) 2.39
Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res (2005) 2.37
An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ. Breast Cancer Res (2009) 2.37
Prospective study of the association of changes in dietary intake, physical activity, alcohol consumption, and smoking with 9-y gain in waist circumference among 16 587 US men. Am J Clin Nutr (2003) 2.29
Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab (2010) 2.27
The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol (2006) 2.24
Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer Res (2009) 2.23
Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res (2009) 2.22
Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. J Clin Oncol (2003) 2.20
HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw (2006) 2.15
Nanochannel electroporation delivers precise amounts of biomolecules into living cells. Nat Nanotechnol (2011) 2.10
In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3. Cancer Res (2006) 2.09
PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res (2014) 2.06
The crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer Cell (2012) 2.02
PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res (2009) 2.01
Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters. Cancer Res (2003) 2.01
Near-infrared fluorescent RGD peptides for optical imaging of integrin alphavbeta3 expression in living mice. Bioconjug Chem (2005) 2.01
Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. J Clin Oncol (2002) 1.99
Alcohol consumption and risk of lung cancer: a pooled analysis of cohort studies. Am J Clin Nutr (2005) 1.97
Epithelial-mesenchymal transition induced by TNF-α requires NF-κB-mediated transcriptional upregulation of Twist1. Cancer Res (2012) 1.97
HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res (2004) 1.89
Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer (2003) 1.87
A thiol-reactive 18F-labeling agent, N-[2-(4-18F-fluorobenzamido)ethyl]maleimide, and synthesis of RGD peptide-based tracer for PET imaging of alpha v beta 3 integrin expression. J Nucl Med (2006) 1.83
Matrix-producing carcinoma of the breast: an aggressive subtype of metaplastic carcinoma. Am J Surg Pathol (2009) 1.79
Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J Natl Cancer Inst (2010) 1.79
Metabolomics in premature labor: a novel approach to identify patients at risk for preterm delivery. J Matern Fetal Neonatal Med (2010) 1.77
NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry. J Natl Compr Canc Netw (2009) 1.73
Rad52-mediated DNA annealing after Rad51-mediated DNA strand exchange promotes second ssDNA capture. EMBO J (2006) 1.72
Selective expression of KrasG12D in granulosa cells of the mouse ovary causes defects in follicle development and ovulation. Development (2008) 1.68
Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype. Clin Cancer Res (2006) 1.67
The association between tooth loss and the self-reported intake of selected CVD-related nutrients and foods among US women. Community Dent Oral Epidemiol (2005) 1.67
Profile of Ets gene expression in human breast carcinoma. Cancer Biol Ther (2007) 1.65
Recommendations for validating estrogen and progesterone receptor immunohistochemistry assays. Arch Pathol Lab Med (2010) 1.64
Introduction of oncogenes into mammary glands in vivo with an avian retroviral vector initiates and promotes carcinogenesis in mouse models. Proc Natl Acad Sci U S A (2006) 1.60
The polarity protein Par6 induces cell proliferation and is overexpressed in breast cancer. Cancer Res (2008) 1.59
Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol (2005) 1.58
Mammary tumorigenesis and metastasis caused by overexpression of insulin receptor substrate 1 (IRS-1) or IRS-2. Mol Cell Biol (2006) 1.58
Lobular neoplasia on core-needle biopsy--clinical significance. Cancer (2004) 1.57
A prospective study of job strain and coronary heart disease in US women. Int J Epidemiol (2002) 1.56
STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas. Breast Cancer Res (2012) 1.56
Development of standard estrogen and progesterone receptor immunohistochemical assays for selection of patients for antihormonal therapy. Appl Immunohistochem Mol Morphol (2007) 1.56
Loss of Par3 promotes breast cancer metastasis by compromising cell-cell cohesion. Nat Cell Biol (2012) 1.53
Nef-mediated resistance of human immunodeficiency virus type 1 to antiviral cytotoxic T lymphocytes. J Virol (2002) 1.51
PIK3CA mutations in in situ and invasive breast carcinomas. Cancer Res (2010) 1.49
Applying the PRECIS criteria to describe three effectiveness trials of weight loss in obese patients with comorbid conditions. Health Serv Res (2011) 1.47
Molecular classification of breast cancer: limitations and potential. Oncologist (2006) 1.46
Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial. J Am Coll Surg (2009) 1.46
Differences in breast cancer risk factors by tumor marker subtypes among premenopausal Vietnamese and Chinese women. Cancer Epidemiol Biomarkers Prev (2005) 1.45
18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation. J Nucl Med (2011) 1.45
Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. Clin Cancer Res (2012) 1.44
Colon cancer: risk perceptions and risk communication. J Health Commun (2004) 1.44
Invasive neuroendocrine carcinoma of the breast: a distinctive subtype of aggressive mammary carcinoma. Cancer (2010) 1.44
Inhibition of lipocalin 2 impairs breast tumorigenesis and metastasis. Cancer Res (2009) 1.43
Human primary ductal carcinoma in situ (DCIS) subtype-specific pathology is preserved in a mouse intraductal (MIND) xenograft model. J Pathol (2011) 1.43
Invasive breast cancer. J Natl Compr Canc Netw (2011) 1.43
Estrogen receptor positive breast cancer metastasis: altered hormonal sensitivity and tumor aggressiveness in lymphatic vessels and lymph nodes. Cancer Res (2006) 1.43
Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res (2004) 1.42
Biological and genetic properties of the p53 null preneoplastic mammary epithelium. FASEB J (2002) 1.42
Caregiving to children and grandchildren and risk of coronary heart disease in women. Am J Public Health (2003) 1.42
Effects of tissue handling on RNA integrity and microarray measurements from resected breast cancers. J Natl Cancer Inst (2011) 1.38
18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. J Nucl Med (2006) 1.37
Red meat consumption during adolescence among premenopausal women and risk of breast cancer. Cancer Epidemiol Biomarkers Prev (2008) 1.36
Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism. Cancer Res (2011) 1.35
Therapy related acute myeloid leukemia in breast cancer survivors, a population-based study. Breast Cancer Res Treat (2009) 1.28
The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J Bone Miner Res (2012) 1.28
Alterations of gene expression in the development of early hyperplastic precursors of breast cancer. Am J Pathol (2007) 1.25